Pioglitazone, an agonist of PPAR γ, reverses doxorubicin-resistance in an osteosarcoma patient-derived orthotopic xenograft model by downregulating P-glycoprotein expression.
This study suggests that the DOX-PIO combination could be used in the clinic for osteosarcoma patients who develop DOX-resistance.
PMID: 31545293 [PubMed - in process]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Higuchi T, Sugisawa N, Miyake K, Oshiro H, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Kline Z, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM Tags: Biomed Pharmacother Source Type: research
More News: Actos | Bone Cancers | Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Multidrug Resistance | Osteosarcoma | Science | Study